Elanco Animal Health awarded Modi Rajeev A. 60 derivative securities at $24.50 per share on September 4, 2026. The transaction leaves a reported holding of 9,831 derivative securities and represents about 0.6% of that resulting position, giving investors the disclosed scale of the award relative to the holding.
Key Highlights
- Modi Rajeev A.’s resulting position was 9,831 derivative securities.
- The award represented about 0.6% of that resulting derivative securities holding.
- Elanco Animal Health Inc. awarded Modi Rajeev A. 60 derivative securities.
- The award occurred on September 4, 2026, at $24.50 per share.
Elanco Animal Health Inc. (NYSE: ELAN) awarded Modi Rajeev A. 60 derivative securities on September 4, 2026. The securities were awarded at $24.50 per share. The transaction date was September 4, 2026.
Resulting Derivative Securities Holding
Following the award, Modi’s resulting holding was 9,831 derivative securities. The transaction represented about 0.6% of that post-transaction position.
FAQs
Q: What did Elanco Animal Health award Modi Rajeev A.?
A: Elanco Animal Health Inc. awarded Modi Rajeev A. 60 derivative securities on September 4, 2026. The securities were awarded at $24.50 per share, and the transaction date was September 4, 2026.
Q: What does the ELAN insider award mean for investors?
A: The disclosed transaction represented about 0.6% of Modi’s resulting derivative securities holding. The record also states that the post-transaction holding was 9,831 derivative securities.
Q: How many derivative securities did Modi hold after the Elanco transaction?
A: After the award, Modi Rajeev A. held 9,831 derivative securities of Elanco Animal Health. The transaction accounted for about 0.6% of that resulting holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.